Thelansis

  Follicular lymphoma (FL) is the second most commonly diagnosed, typically affecting individuals around 65 at presentation. Approximately 80% of patients with FL have a chromosomal abnormality known as t(14;18), which leads to the overexpression of the B-cell lymphoma 2 (BCL-2) protein. Most patients with low-grade FL (grade 1, 2, or 3A) are diagnosed at an advanced disease stage. However, treatment may not be necessary unless patients develop symptoms, organ function impairment, or symptomatic cytopenias. When treatment is required for patients with advanced-stage FL, several chemoimmunotherapeutic combinations can be used, including rituximab or obinutuzumab with cyclophosphamide, vincristine, and prednisone (CVP); rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-R); or bendamustine plus rituximab (BR) or obinutuzumab, which have shown non-inferiority to conventional chemoimmunotherapy regimens. Another option is the combination of lenalidomide a...